NICE blocks immunotherapy drug nivolumab (Opdivo) for kidney cancer
Decision comes despite nivolumab being accepted for the Early Access to Medicines Scheme (EAMS) based upon some impressive Phase III clinical trial results.
Disappointing news for kidney cancer patients: NICE has issued an interim decision not to recommend the immunotherapy drug nivolumab (Opdivo) as a second-line treatment for metastatic kidney cancer, despite it’s proven effectiveness at prolonging the life of kidney cancer patients. In their Appraisal Consultation Document (ACD) released today, NICE has made the decision that nivolumab is too expensive to be prescribed for NHS patients. This decision comes despite nivolumab being accepted for the Early Access to Medicines Scheme (EAMS) based upon some impressive Phase III clinical trial results.
There is some hope, however, that nivolumab might enter the new Cancer Drugs Fund (CDF), which becomes operational this month. This will be on the proviso that the manufacturer, Bristol-Myers Squibb, is able to prove the cost-effectiveness of nivolumab during the 24 months that the drug will be funded by the CDF. This decision will be made at a second NICE appraisal meeting to be held early next month, after which NICE will release its final appraisal decision in October. It is well known that a clinical response to cancer drugs is individual, and some patients respond better than others; the Kidney Cancer Support Network (KCSN) believe that clinicians need to have a choice of drugs to be able to effectively treat kidney cancer patients. NICE’s decision leaves clinicians with a very limited choice, and is denying patients access to a new and innovative class of drug with proven long-term benefits in about one third of cases. This decision also has a profound effect on the way England treats cancer patients, leaving people with kidney cancer at a significant disadvantage and more likely to die prematurely compared to the rest of Europe and America. KCSN calls upon NICE to review its procedures for the appraisal of drugs for rare and less common cancers. The current appraisal system is unsuitable for small patient populations, and has been shown to be unfair to different groups of patients, denying rare cancer patients access to life-prolonging treatments during the most difficult time for both them and their families. “Not only is today’s news deeply distressing for kidney cancer patients and their families, it demonstrates the current frustrating and fragmented approach to reviewing cancer medicines in the UK,” said Rose Woodward from the KCSN. “Despite the fact NICE has recognised the benefits of nivolumab for skin cancer patients, and despite hearing first-hand the difference nivolumab is making to kidney cancer patients here and in other countries, NICE is set to block access. An urgent review of this decision is needed and I sincerely hope everyone involved will work hard to reverse this decision and get this drug to the kidney cancer patients who need it.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance